Gene mutation profiling of primary glioblastoma through multiple tumor biopsy guided by 1H-magnetic resonance spectroscopy

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 5, 2015, Pages 5327-5335

  Tang, Chao ^a   Guo, Jun ^a   Chen, Hong ^a   Yao, Cheng Jun ^a   Zhuang, Dong Xiao ^a   Wang, Yin ^a   Tang, Wei Jun ^a   Ren, Guang ^a   Yao, Yu ^a   Wu, Jin Song ^a   Mao, Ying ^a   Zhou, Liang Fu ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Biopsy; Glioblastoma multiforme; Heterogeneity; Mutation profi ling; Proton magnetic resonance spectroscopy

Indexed keywords

ASPARTIC ACID; CHOLINE; N-ACETYLASPARTATE; STOP CODON; TUMOR MARKER;

ADOLESCENT; ADULT; ANALOGS AND DERIVATIVES; BRAIN TUMOR; CANCER GRADING; CHEMISTRY; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; GENETICS; GLIOBLASTOMA; HUMAN; IMAGE GUIDED BIOPSY; MALE; MIDDLE AGED; MISSENSE MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHENOTYPE; PROCEDURES; PROTON NUCLEAR MAGNETIC RESONANCE; STOP CODON; YOUNG ADULT;

ADOLESCENT; ADULT; ASPARTIC ACID; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CHOLINE; CODON, NONSENSE; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; GLIOBLASTOMA; HUMANS; IMAGE-GUIDED BIOPSY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM GRADING; PHENOTYPE; PROTON MAGNETIC RESONANCE SPECTROSCOPY; YOUNG ADULT;

EID: 84937840507     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Clarke J, Butowski N, Chang S. Recent advances in therapy for glioblastoma. Arch Neurol 2010; 67: 279-83.
2. Bai RY, Staedtke V, Riggins GJ. Molecular targeting of glioblastoma: Drug discovery and therapies. Trends Mol Med 2011; 17: 301-12.
3. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN. Integrated genomic analysis identififies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
4. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-92.
5. Bonavia R, Inda MM, Cavenee WK, Furnari FB. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res 2011; 71: 4055-60.
6. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC, Curtis C, Watts C, Tavare S. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A 2013; 110: 4009-14.
7. Grasbon-Frodl EM, Kreth FW, Ruiter M, Schnell O, Bise K, Felsberg J, Reifenberger G, Tonn JC, Kretzschmar HA. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer 2007; 121: 2458-64.
8. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O'Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L. The somatic genomic landscape of glioblastoma. Cell 2013; 155: 462-477.
9. Bulik M, Jancalek R, Vanicek J, Skoch A, Mechl M. Potential of MR spectroscopy for assessment of glioma grading. Clin Neurol Neurosurg 2013; 115: 146-53.
10. Liu X, Mody K, de Abreu FB, Pipas JM, Peterson JD, Gallagher TL, Suriawinata AA, Ripple GH, Hourdequin KC, Smith KD, Barth RJ, Colacchio TA, Tsapakos MJ, Zaki BI, Gardner TB, Gordon SR, Amos CI, Wells WA, Tsongalis GJ. Molecular profifiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations. Clin Chem 2014; 60: 1004-11.
11. Tabone T, Abuhusain HJ, Nowak AK, Erber WN, McDonald KL. Multigene profifiling to identify alternative treatment options for glioblastoma: a pilot study. J Clin Pathol 2014; 67: 550-5.
12. Guo J, Yao C, Chen H, Zhuang D, Tang W, Ren G, Wang Y, Wu J, Huang F, Zhou L. The relationship between Cho/NAA and glioma metabolism: implementation for margin delineation of cerebral gliomas. Acta Neurochir (Wien) 2012; 154: 1361-70.
13. Boman BM, Fields JZ. An APC: WNT counter-current-like mechanism regulates cell division along the human colonic crypt axis: a mechanism that explains how apc mutations induce proliferative abnormalities that drive colon cancer development. Front Oncol 2013; 3: 244.
14. Yates LR, Campbell PJ. Evolution of the cancer genome. Nat Rev Genet 2012; 13: 795-806.
15. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-73.
16. Weber GL, Parat MO, Binder ZA, Gallia GL, Riggins GJ. Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Oncotarget 2011; 2: 833-49.
17. Porto L, Kieslich M, Franz K, Lehrnbecher T, Zanella F, Pilatus U, Hattingen E. MR spectroscopy differentiation between high and low grade astrocytomas: a comparison between paediatric and adult tumours. Eur J Paediatr Neurol 2011; 15: 214-21.
18. Magalhaes A, Godfrey W, Shen Y, Hu J, Smith W. Proton magnetic resonance spectroscopy of brain tumors correlated with pathology. Acad Radiol 2005; 12: 51-7.
19. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander HM, Su SM. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739-44.
20. Vander HM, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-33.
21. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012; 21: 297-308.
22. Weise LM, Harter PN, Eibach S, Braczynski AK, Dunst M, Rieger J, Bahr O, Hattingen E, Steinbach JP, Plate KH, Seifert V, Mittelbronn M. Confounding factors in diagnostics of MGMT promoter methylation status in glioblastomas in stereotactic biopsies. Stereotact Funct Neurosurg 2014; 92: 129-39.